SIRS 2025: Insights on Schizophrenia Research, From Rights Based Care to Digital Biomarkers Michael Spilka, Sr. Clinical Scientist This year’s Schizophrenia International Research Society (SIRS) 2025 Congress in Chicago brought together leading scientists and researchers, exploring the latest advancements and ongoing challenges in understanding and addressing schizophrenia. Michael Spilka, PhD. shares his key insights from […]

The post SIRS 2025: Insights on Schizophrenia Research, From Rights Based Care to Digital Biomarkers appeared first on Cambridge Cognition.

Spin-out Monument Therapeutics Announces Appointment of Robert Radie as Chair and Heather Preston to Advisory Board Thursday 17th April Manchester, UK, 17 April 2024 – Monument Therapeutics, a precision, neuroscience company focused on the development of innovative treatments forserious central nervous system disorders (CNS), today announced two key leadership appointments. Robert S. Radie (Bob) has […]

The post Monument Therapeutics Announces Appointment of Robert Radie as Chair and Heather Preston to Advisory Board appeared first on Cambridge Cognition.

Dementias Platform UK: TRANSLATION 2025 Martina De Lillo, Clinical Scientist We recently attended TRANSLATION 2025, organized by Dementia Platform UK, where experts shared groundbreaking developments in treatment approaches, diagnostic methods, and research methodologies. The presentations revealed a field undergoing rapid transformation, with significant implications for patients and healthcare professionals alike. The theme of the conference […]

The post Dementias Platform UK: TRANSLATIONS 2025 appeared first on Cambridge Cognition.

When to Use Standardised Assessments—And When You Might Need to Build Your Own Alex Kaula, Senior R&D Scientist Hello, I’m Alex Kaula, Senior R&D Scientist at Cambridge Cognition. If your research involves measuring cognitive function or clinical outcomes, you’ve likely faced this question: Should I use an established, validated assessment, or create a new one […]

The post When to Use Standardised Assessments—And When You Might Need to Build Your Own appeared first on Cambridge Cognition.

Cambridge Cognition Secures £1million Contract for Phase 3 Autoimmune Disease Trial 10 April 2025 Cambridge Cognition (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment, has been selected by a major pharmaceutical company to provide digital cognitive assessments for a large Phase 3 autoimmune disease clinical […]

The post Cambridge Cognition Secures £1million Contract for Phase 3 Autoimmune Disease Trial appeared first on Cambridge Cognition.

Cambridge Cognition selected for two Phase 3 Trials combining digital cognitive and voice solutions 3rd April 2025 Cambridge Cognition (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment, has been selected by a major pharmaceutical company to provide digital cognitive and voice assessments for two Phase […]

The post Cambridge Cognition selected for two Phase 3 trials combining digital cognitive and voice solutions  appeared first on Cambridge Cognition.

Cambridge Cognition selected for two Phase 3 Trials combining digital cognitive and voice solutions 3rd April 2025 Cambridge Cognition (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment, has been selected by a major pharmaceutical company to provide digital cognitive and voice assessments for two Phase […]

The post Cambridge Cognition selected for two Phase 3 trials combining digital cognitive and voice solutions  appeared first on Cambridge Cognition.

SIRS 2025 | Posters & Presentations Chicago, IL. USA | 29th March – 2nd April 2025 Be the first to gain access to new data and insights, presented at SIRS 2025. Access Posters Sunday 30th March 12:00-14:00 S162 – Identification of Robust Speech-Based Markers of Negative Symptom Severity in Schizophrenia Spectrum Disorders, by Michael Spilka […]

The post SIRS 2025 | Posters & Presentations appeared first on Cambridge Cognition.

AD/PD 2025 | Posters & Presentations Vienna, Austria | 1st-5th April 2025 Be the first to gain access to new data and insights, presented at AD/PD 2025. Access Posters This year at AD/PD, we can’t wait to share our latest research with you with poster presentations from Emily Thorp, Francesca Cormack and Nick Taptiklis.  2nd-3rd […]

The post AD/PD 2025 | Posters & Presentations appeared first on Cambridge Cognition.

Actigraphy and wearable sensor technologies to enhance assessment in health conditions affecting motor function and behaviour Reflections from the 2025 Actigraph Digital Data Summit​ The 2025 @Actigraph Digital Data Summit in Pensacola, FL, provided a valuable environment for exploring the potential and challenges of using actigraphy, and other wearable sensor technologies, to enhance assessment in […]

The post Actigraphy and wearable sensor technologies to enhance assessment in health conditions appeared first on Cambridge Cognition.

CANTAB® demonstrates substantial value in one of the largest brain health studies ever conducted 6 March 2025 Cambridge Cognition (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment, announces its involvement in one of the world’s largest brain health studies, the Intuition Brain Health study1, demonstrating […]

The post CANTAB® demonstrates substantial value in one of the largest brain health studies ever conducted  appeared first on Cambridge Cognition.

Monument Therapeutics secures £850k to advance breakthrough schizophrenia treatment 25 February 2025 Manchester, 25th February 2025 — Monument Therapeutics, an innovative neuroscience company applying digital biomarkers to psychiatric drug development, has secured £850k in further funding led by ACF Investors, with participation from Wren Capital, o2h Ventures, and angel investors. The investment will be used […]

The post Monument Therapeutics secures £850k to advance breakthrough schizophrenia treatment appeared first on Cambridge Cognition.

Cambridge Cognition submits FDA Letter of Intent for Cognitive Impairment Assessments in Schizophrenia 18 February 2025 Cambridge Cognition (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment, has submitted a Letter of Intent to the U.S. Food and Drug Administration (FDA) under the Drug Development Tool […]

The post Cambridge Cognition submits FDA Letter of Intent for Cognitive Impairment Assessments in Schizophrenia appeared first on Cambridge Cognition.

ISCTM | 21st Annual Scientific Meeting Washington, D.C., USA | 19-21 February 2025 About the ISCTM The International Society for CNS Clinical Trials and Methodology (ISCTM) is an independent multi-disciplinary organization devoted to promoting advances in, and dissemination of, clinical research methods related to development and use of CNS therapeutics. The ISCTM accomplishes this by […]

The post ISCTM 2025 appeared first on Cambridge Cognition.

Cambridge Cognition Launches In-House Rater Training Digital Measures that Matter Cambridge Cognition is excited to announce a new service that will help transform the quality and efficiency of brain health research. Our new Rater Training service combines with our existing digital tools to create a more streamlined and accurate way to conduct clinical studies focused […]

The post Cambridge Cognition Launches In-House Rater Training appeared first on Cambridge Cognition.

Actinogen Enhances Phase 2b/3 Alzheimer’s Trial with Our Full Digital Suite Digital Measures that Matter Cambridge Cognition is excited to announce the expansion of its partnership with Actinogen Medical Limited for the Phase 2b/3 XanaMILA Alzheimer’s disease trial. Building on the successful integration of Cambridge Cognition’s full product suite including Cognitive Assessments (CANTAB), electronic Clinical […]

The post Actinogen Enhances Phase 2b/3 Alzheimer’s Trial with Cambridge Cognition’s Full Digital Suite appeared first on Cambridge Cognition.

Cambridge Cognition Highlights positive CANTAB® Results in research by Bristol Myers Squib Digital Measures that Matter Cambridge Cognition congratulates Bristol Myers Squibb for its recent FDA approval of Cobenfy (KarXT™ or Xanomeline and Trospium) and the exciting results published recently in The American Journal of Psychiatry1 showcasing the use of CANTAB® in two Phase III […]

The post Cambridge Cognition Highlights positive CANTAB® Results in research by Bristol Myers Squib appeared first on Cambridge Cognition.

Enhancing Patient Outcomes in ADRD Digital Measures that Matter As the landscape for Alzheimer’s Disease and Related Dementias (ADRD) treatment evolves, it’s crucial to align clinical research with the experiences and needs of patients and their care partners. The Digital Medicine Society’s (DiMe) Core Digital Measures of ADRD conceptual model provides a patient-centred framework for […]

The post Enhancing Patient Outcomes in ADRD: Digital Measures that Matter appeared first on Cambridge Cognition.

Exploring Innovation in Alzheimer’s Disease Research Highlights from CTAD 2024 17th Clinical Trials on Alzheimer’s Disease (CTAD) Madrid (Spain) October 29 – November 1, 2024 Last week, our team travelled to Madrid to participate in the 17th Clinical Trials on Alzheimer’s Disease (CTAD) conference, where we had the opportunity to present our latest research and […]

The post Exploring Innovation in Alzheimer’s Disease Research: Highlights from CTAD 2024 appeared first on Cambridge Cognition.

CTAD24 | Posters & Content Madrid, Spain | 29 October – 1 November 2024 This week, our team traveled to Madrid to attend CTAD 2024, where they presented several posters and hosted a session on Validating Speech-Based Biomarkers for Measuring Disease Progression in Alzheimer’s Disease (AD). These materials are now available for you to access […]

The post CTAD24 | Posters & Content appeared first on Cambridge Cognition.